225 related articles for article (PubMed ID: 25643258)
1. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
Li W; Zhao XL; Shang SQ; Shen HQ; Chen X
Curr Cancer Drug Targets; 2015; 15(3):196-204. PubMed ID: 25643258
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
[TBL] [Abstract][Full Text] [Related]
3. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
O' Reilly E; Dhami SPS; Baev DV; Ortutay C; Halpin-McCormick A; Morrell R; Santocanale C; Samali A; Quinn J; O'Dwyer ME; Szegezdi E
Sci Rep; 2018 Oct; 8(1):15752. PubMed ID: 30361682
[TBL] [Abstract][Full Text] [Related]
4. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
5. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C
Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
Hu XY; Liang JY; Guo XJ; Liu L; Guo YB
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):146-53. PubMed ID: 25363523
[TBL] [Abstract][Full Text] [Related]
7. Targeting Inflammation, PHA-767491 Shows a Broad Spectrum in Protein Aggregation Diseases.
Chung YH; Lin CW; Huang HY; Chen SL; Huang HJ; Sun YC; Lee GC; Lee-Chen GJ; Chang YC; Hsieh-Li HM
J Mol Neurosci; 2020 Jul; 70(7):1140-1152. PubMed ID: 32170713
[TBL] [Abstract][Full Text] [Related]
8. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
[TBL] [Abstract][Full Text] [Related]
9. A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation.
Chen EW; Tay NQ; Brzostek J; Gascoigne NRJ; Rybakin V
Front Immunol; 2019; 10():1718. PubMed ID: 31402912
[TBL] [Abstract][Full Text] [Related]
10. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
[TBL] [Abstract][Full Text] [Related]
11. Cdc7-dependent and -independent phosphorylation of Claspin in the induction of the DNA replication checkpoint.
Rainey MD; Harhen B; Wang GN; Murphy PV; Santocanale C
Cell Cycle; 2013 May; 12(10):1560-8. PubMed ID: 23598722
[TBL] [Abstract][Full Text] [Related]
12. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
[TBL] [Abstract][Full Text] [Related]
14. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.
Guo Y; Wang J; Benedict B; Yang C; van Gemert F; Ma X; Gao D; Wang H; Zhang S; Lieftink C; Beijersbergen RL; Te Riele H; Qiao X; Gao Q; Sun C; Qin W; Bernards R; Wang C
Genome Med; 2021 Oct; 13(1):166. PubMed ID: 34663432
[TBL] [Abstract][Full Text] [Related]
15. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.
Sasi NK; Tiwari K; Soon FF; Bonte D; Wang T; Melcher K; Xu HE; Weinreich M
PLoS One; 2014; 9(11):e113300. PubMed ID: 25412417
[TBL] [Abstract][Full Text] [Related]
16. Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
Wang Z; Gu C; Wang X; Lang Y; Wu Y; Wu X; Zhu X; Wang K; Yang H
Med Oncol; 2019 Oct; 36(12):97. PubMed ID: 31664534
[TBL] [Abstract][Full Text] [Related]
17. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
18. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
Chen XZ; Cao ZY; Chen TS; Zhang YQ; Liu ZZ; Su YT; Liao LM; Du J
Oncol Rep; 2012 Aug; 28(2):742-8. PubMed ID: 22641337
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
Cheng AN; Lo YK; Lin YS; Tang TK; Hsu CH; Hsu JT; Lee AY
EBioMedicine; 2018 Oct; 36():241-251. PubMed ID: 30293817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
